ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer’s Disease Testing
“This agreement further strengthens ALZpath’s leadership in blood-based Alzheimer’s testing and reinforces our position as the foundational component supporting the overwhelming majority of the pTau217 IVD market,” said Mike Banville, CEO of ALZpath.
June 24, 2026